The global cholesterol test market size was valued at USD 8.85 billion in 2025 and is projected to grow from USD 9.50 billion in 2026 to USD 16.83 billion by 2034, registering a CAGR of 7.4% during the forecast period from 2026 to 2034. North America dominated the cholesterol test market with a market share of 38.6% in 2025.
A cholesterol test, also known as a lipid panel or lipid profile, is a blood test used to measure cholesterol levels and other fats in the bloodstream. It evaluates total cholesterol, low-density lipoprotein (LDL or "bad" cholesterol), high-density lipoprotein (HDL or "good" cholesterol), and triglycerides. This test is crucial for assessing the risk of cardiovascular diseases such as heart attacks and strokes.
Regular monitoring of cholesterol levels helps in early detection and management of hyperlipidemia, guiding lifestyle changes or medical interventions to maintain heart health.
Download a Free Sample To learn more about this report,
Rising Demand for Cholesterol Testing
The study of lipid profiles in biological systems (lipidomics) is emerging as a significant area in diagnosis. This developing field of science allows for a more thorough examination of lipids, aiding in the early diagnosis and treatment of cardiovascular diseases.
This increasing demand in lipidomics is set to significantly increase demand for cholesterol testing, providing more accurate results in early diagnosis.
Shift towards Integration of AI in Cholesterol Testing
The integration of artificial intelligence into cholesterol testing revolutionizes the cardiovascular health assessment procedure. AI refines the old cholesterol testing technique by providing highly accurate, prompt, and personalized results.
Such a research study illustrates that integrating AI into cholesterol testing enhances diagnostic precision, thus leading to efficient and personalized cardiovascular care.
Increasing Prevalence of Cardiovascular Diseases
The increasing prevalence of cardiovascular disease has boosted the demand for cholesterol testing, as these tests are crucial in diagnosing cardiovascular conditions and analyzing lipid profiles. An abnormal cholesterol level can lead to serious outcomes, such as heart attack and stroke.
Thus, the growing prevalence of cardiovascular diseases and the global demand for improved cholesterol testing are driving the market.
Government Initiatives for Cholesterol Testing
Many countries have launched public awareness campaigns and established guidelines for conducting regular cholesterol tests. This strategy aims to increase accessibility to cholesterol testing, educate the public about monitoring lipid levels, and integrate cholesterol testing into national health agendas.
Such government initiatives are crucial for improving countries’ health infrastructure and overall patient outcomes.
Expensive Procedures for Cholesterol Testing
The high cost of cholesterol testing is a significant challenge for the global market. Advanced diagnostic platforms like lipidomic profiling and AI-driven cholesterol assessments require sophisticated equipment and highly trained personnel, driving up the cost of testing. This financial barrier limits access to regular cholesterol screenings, especially in low-resource settings, reducing early detection and prevention of cardiovascular diseases.
Technological Advancements in Cholesterol Testing Devices
New technologies that improve test device accuracy, speed, and ease open opportunities in the global cholesterol test industry. The portable, handheld cholesterol test tools facilitate easier access for healthcare providers and end-users to provide quick results in multiple settings, from the hospital to use at home. Innovations in cholesterol testing devices are creating significant market opportunities. Portable and handheld cholesterol test kits provide fast, reliable results, enabling point-of-care testing in clinics, pharmacies, and at home. These advancements improve patient compliance and promote proactive health monitoring, particularly for individuals at risk of cardiovascular diseases.
This growing demand for advanced technologies presents a lucrative market opportunity for cholesterol testing.
Limited Awareness and Low Adoption of Preventive Cholesterol Screening in Developing Regions
Despite the increasing prevalence of cardiovascular diseases, cholesterol testing remains underutilized in many low- and middle-income countries due to limited public awareness, inadequate preventive healthcare programs, and restricted access to diagnostic facilities. Many individuals undergo cholesterol testing only after developing symptoms or being diagnosed with cardiovascular conditions, reducing the effectiveness of early intervention. In addition, insufficient reimbursement policies and disparities in healthcare infrastructure further limit routine lipid screening, particularly in rural and underserved areas.
As a result, delayed diagnosis and inconsistent preventive screening continue to hinder the widespread adoption of cholesterol testing, posing a significant challenge to the global cholesterol test market growth.
Request Customizationto receive a tailored report.
Testing Kits Dominated the Market with 48.3% Share in 2025
Testing kits accounted for the largest share of the global cholesterol test market at 48.3% in 2025, valued at USD 4.27 billion. The segment's dominance is attributed to the widespread adoption of rapid diagnostic kits, increasing preventive health screening, and growing demand for convenient point-of-care and home-based cholesterol testing solutions.
Total Cholesterol Tests Held the Largest Market Share at 31.7% in 2025
The total cholesterol tests segment held the largest market share of 31.7% in 2025, reaching USD 2.81 billion. The segment continues to lead due to its routine use in cardiovascular risk assessment, annual health check-ups, and preventive screening programs across hospitals and diagnostic laboratories.
Diabetes is Projected to Register the Fastest Growth at a CAGR of 8.8%
The diabetes segment is expected to witness the fastest growth, registering a CAGR of 8.8% during 2026–2034. Rising diabetes prevalence, increased risk of dyslipidemia among diabetic patients, and the growing emphasis on routine lipid monitoring are driving demand for cholesterol testing in diabetes management.
Hospitals and Clinics Dominated the Market with 41.5% Share in 2025
Hospitals and clinics accounted for the largest share of the global cholesterol test market at 41.5% in 2025, valued at USD 3.67 billion. The segment is driven by high patient volumes, comprehensive cardiovascular screening services, and the availability of advanced diagnostic infrastructure for lipid profile testing.
Speak to an Analystto discuss market opportunities.
North America dominated the global cholesterol test market with a 38.6% market share, valued at USD 3.42 billion in 2025. The region benefits from a high prevalence of cardiovascular diseases, widespread preventive health screening programs, advanced diagnostic infrastructure, and strong awareness of lipid monitoring. Favorable reimbursement policies and increasing adoption of point-of-care cholesterol testing continue to support market growth.
The United States accounted for an estimated USD 2.94 billion of the market in 2025, making it the largest contributor in North America. Growth is driven by rising cardiovascular disease prevalence, routine cholesterol screening initiatives, increasing adoption of home-based lipid testing, and the presence of leading diagnostic manufacturers and clinical laboratory networks.
Canada generated an estimated USD 0.48 billion in 2025. Growing government support for preventive healthcare, increasing awareness of cardiovascular risk management, and expanding access to diagnostic services are driving demand for cholesterol testing across hospitals, clinics, and diagnostic laboratories.
Europe accounted for 27.2% of the global cholesterol test market share, reaching USD 2.41 billion in 2025. The market is supported by well-established healthcare systems, increasing cardiovascular disease screening programs, growing emphasis on preventive healthcare, and rising adoption of advanced laboratory diagnostic technologies.
The United Kingdom represented an estimated USD 0.42 billion in 2025. The country's market is driven by NHS preventive screening initiatives, increasing public awareness of heart health, and growing demand for early lipid profile testing to reduce cardiovascular disease burden.
Germany generated an estimated USD 0.56 billion in 2025, making it one of the leading contributors in Europe. The country's advanced healthcare infrastructure, high healthcare expenditure, increasing laboratory automation, and strong focus on preventive diagnostics continue to support market expansion.
Asia Pacific accounted for 23.1% of the global market, valued at USD 2.04 billion in 2025, and is projected to register the fastest CAGR of 9.8% during the forecast period. Rapid urbanization, rising healthcare expenditure, increasing incidence of obesity and cardiovascular diseases, and expanding diagnostic infrastructure are accelerating market growth across the region.
Japan generated an estimated USD 0.47 billion in 2025. The country's aging population, high prevalence of lifestyle-related diseases, regular health check-up culture, and strong adoption of advanced diagnostic technologies continue to drive demand for cholesterol testing.
China accounted for an estimated USD 0.95 billion in 2025, making it the largest market in Asia Pacific. Government healthcare reforms, expanding hospital infrastructure, growing health awareness, and increasing investments in preventive healthcare are supporting strong market growth.
The Middle East & Africa represented 4.7% of the global cholesterol test market, totaling USD 0.42 billion in 2025. Rising investments in healthcare infrastructure, increasing awareness of cardiovascular disease prevention, expanding diagnostic laboratory networks, and improving access to preventive screening services are supporting regional market growth.
The United Arab Emirates (UAE) accounted for an estimated USD 0.12 billion in 2025. The market is driven by government investments in healthcare modernization, increasing prevalence of lifestyle-related disorders, growing adoption of preventive health check-ups, and expansion of advanced diagnostic facilities.
Latin America accounted for 6.4% of the global cholesterol test market, reaching USD 0.57 billion in 2025. Rising awareness of cardiovascular health, improving healthcare access, increasing chronic disease prevalence, and expanding diagnostic laboratory services are contributing to steady regional market growth.
Brazil generated an estimated USD 0.24 billion in 2025, making it the largest market in Latin America. Increasing government initiatives for non-communicable disease prevention, expanding private diagnostic laboratory networks, and rising adoption of routine cholesterol screening continue to strengthen market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com